Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 29,244 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 29,244 shares of Sight Sciences stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $108,202.80. Following the transaction, the chief executive officer owned 6,151,156 shares in the company, valued at approximately $22,759,277.20. This represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Paul Badawi also recently made the following trade(s):

• On Friday, January 16th, Paul Badawi sold 22,362 shares of Sight Sciences stock. The stock was sold at an average price of $6.62, for a total value of $148,036.44.
• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total value of $88,787.60.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $3.52 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.22 and a quick ratio of 9.52. The business’s 50-day simple moving average is $4.82 and its 200-day simple moving average is $5.73. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $9.24. The stock has a market capitalization of $190.12 million, a PE ratio of -4.69 and a beta of 2.50.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%.The business had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.35 million. Sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in Sight Sciences during the 1st quarter worth about $128,000. Strs Ohio bought a new position in shares of Sight Sciences in the 1st quarter valued at about $158,000. Rhumbline Advisers increased its position in shares of Sight Sciences by 9.5% in the first quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock valued at $120,000 after acquiring an additional 4,319 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sight Sciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock valued at $3,494,000 after acquiring an additional 43,791 shares during the last quarter. Finally, Intech Investment Management LLC raised its holdings in Sight Sciences by 26.2% during the second quarter. Intech Investment Management LLC now owns 25,366 shares of the company’s stock worth $105,000 after acquiring an additional 5,261 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SGHT shares. William Blair reaffirmed an “outperform” rating on shares of Sight Sciences in a research report on Thursday, March 5th. Raymond James Financial set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. Citigroup decreased their price objective on Sight Sciences from $9.10 to $6.50 and set a “neutral” rating for the company in a report on Friday, March 6th. Cantor Fitzgerald set a $8.00 target price on Sight Sciences in a research report on Monday, March 2nd. Finally, Piper Sandler set a $9.00 target price on Sight Sciences in a research note on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.31.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.